07 November 2019
Visiongain has launched a new pharma report “Sarcoma Drugs Market Report 2020-2030” Prospects by Treatment Type (Chemotherapy, Targeted Therapy, Anti-angiogenesis drugs, Radiation Therapy), and Geography.
Global sarcoma drugs market is projected to grow on account of growing adoption of novel drugs, rising incidences of soft tissue sarcomas, and presence of strong development pipeline among other contributing factors. The global market is projected to grow at a lucrative CAGR of ~9% and anticipated to surpass USD 850 Million by 2020.
Sarcomas are rare connective tissue tumors that affect any part of the body, including bones, nerves, tendons, muscle, and hair. While sarcomas constitute a heterogeneous group of more than 50 distinct histological subtypes, soft tissue sarcomas (STS) account for over 85% of all cases of sarcoma, while malignant bone sarcomas account for close to 15% of all cases. Globally, STS's annual rate of occurrence is 2-3 per 100,000. Risk factors include genetic mutation such as inherited defects in TP53 gene, APC gene, and RB1 gene, compromised lymph system, radiation, and chemical exposure,
In 2017, the U.S. reported over 12,500 fresh diagnoses and 5,000 deaths from STS. There were more than 3,300 new cases of bone sarcomas and 1,650 deaths in 2017. The risk of developing a sarcoma in life is around 0.4%. In the age group of 0-35 years, approximately 45% of bone sarcomas and 20% of STS are diagnosed.
The demand for sarcoma drugs is gaining interest due to growing patient assistance programs, new product launches by large pharmaceutical companies and the rising focus of these companies on R&D, which contributes to the development of new and advanced therapies.
However, over the past 10 years, the price of prescription drugs has increased steadily, sometimes at a double-digit level. This has led to an increase in total spending on health care, making drugs disproportionately inaccessible for those with limited resources.
In 2018 over 45 million Americans did not have health coverage, according to the Kaiser Family Foundation, and millions of people were underinsured, with 8 out of 10 uninsured persons coming from salaried families. 4 out of 10 individuals who are 65 years of age or younger and 1 out of 3 people over the age of 65 had no drug medication coverage among those with health insurance.
The Patient Assistance Programs (PAPs) have emerged to help patients without health insurance and prescription drug coverage to access the treatment they need. Such services are generally provided by pharmaceutical companies that provide prescription drugs free or low-cost to patients suffering from severe illnesses. Most states offer services for prescription assistance that vary from state to state and care for the aged, disabled, or those in financial need. Many services are condition-specific, such as leukemia.
Targeted therapy and chemotherapy regimens are currently the 2 most popular forms of therapeutics in the market for sarcoma drugs. Between the two, due to its higher effectiveness, the targeted therapy is expected to see greater adoption in the near future. These therapies use immune-formulated drugs and antibodies to inhibit the proliferation of dangerous cancer cells while leaving the normal cells undamaged.
In 2018, U.S. dominated the sarcoma drugs market and is anticipated to maintain the leading position over the forecast period. Some of the factors responsible for its dominating position are fresh product releases during the forecast period, increased acceptance of new treatments, and the involvement of key manufacturers in the U.S. EU5 has a major market share and is likely to show substantial growth over the forecast period. It is expected that there will be a greater understanding of tumor microenvironment, further promoting the development of new patient-specific therapies in the coming years.
Some of the major players operating in this industry are Bayer, Bristol-Myers Squibb, Celgene Corporation, Eisai, Eli Lilly and Company, Genentech USA, GlaxoSmithKline, Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Novartis, Pfizer, Inc., and Teva Pharmaceuticals among other prominent players.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.